The earnings call highlighted strong revenue growth and strategic achievements, such as the Xellia acquisition and pipeline advancements, but was tempered by declines in operating profit and cash flow, as well as margin pressures in the Injectables segment.

Company Guidance

The guidance provided in the call emphasized Hikma's robust financial performance and strategic positioning in the first half of 2025. The company reported a 6% revenue growth despite a 7% decline in core operating profit to $373 million, attributing this to regional and product mix, FX headwinds, and the previous year's strong performance. Core EBITDA and core basic earnings per share both declined by 5% year-on-year. Operating cash flow decreased to $161 million from $198 million, mainly due to the timing of tax payments. Segmental performance was highlighted, with Injectables showing a 12% revenue growth, but a decline in core operating margin to 30%. The Branded business saw a 4% revenue growth and a slight contraction in gross margin. The Rx segment faced an 11% contraction in gross profit due to price erosion. Despite these challenges, Hikma reiterated its full-year guidance, expecting 4% to 6% revenue growth and core operating profit between $730 million to $770 million. The company is focusing on strategic investments and pipeline development, aiming for long-term growth and profitability.

Revenue Growth and Strategic Acquisitions

Revenue grew by 6% in the first half of 2025, driven by robust volumes across all business segments and regions, with recent launches and the fully integrated Xellia acquisition contributing to growth.

Injectables Segment Performance

The Injectables segment saw a 12% core revenue growth year-on-year, with strong growth in European (26%) and MENA (16%) businesses. The Xellia acquisition and new product launches were key contributors.

Branded Segment Momentum

The Branded segment achieved 4% growth on the top line and 3% operating profit growth, maintaining a significant market position in MENA. The company launched 14 products and made 36 regulatory filings in the first half.

Strong Pipeline Developments

Received U.S. FDA approval for TYZAVAN and ustekinumab, expanded the Zagreb pipeline from 9 to 22 active projects, and initiated the first value-added medicine project equivalent to the 505(b)(2) filing in the U.S.

Hikma Pharmaceuticals (GB:HIK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:HIK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2025 (Q4)	- / -	0.467	―	―	―
Aug 07, 2025	2025 (Q2)	0.91 / 0.91	0.946	-3.94% (-0.04)	―	―
Feb 26, 2025	2024 (Q4)	- / 0.47	0.214	118.22% (+0.25)	―	―
Aug 08, 2024	2024 (Q2)	- / 0.95	0.952	-0.70% (>-0.01)	―	―
Feb 22, 2024	2023 (Q4)	- / 0.21	0.887	-75.87% (-0.67)	―	―
Aug 03, 2023	2023 (Q2)	0.71 / 0.95	0.683	39.48% (+0.27)	―	―
Feb 23, 2023	2022 (Q4)	0.58 / 0.66	0.722	-8.56% (-0.06)	―	―
Aug 04, 2022	2022 (Q2)	0.72 / 0.68	0.715	-4.58% (-0.03)	―	―
Feb 24, 2022	2021 (Q4)	0.72 / 0.72	0.663	8.99% (+0.06)	―	―
Aug 06, 2021	2021 (Q2)	0.67 / 0.72	0.631	13.33% (+0.08)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:HIK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	1856.37p	1724.34p	-7.11%
Feb 26, 2025	2222.09p	2084.66p	-6.18%
Aug 08, 2024	1759.53p	1904.88p	+8.26%
Feb 22, 2024	1873.76p	1953.97p	+4.28%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Hikma Pharmaceuticals PLC (GB:HIK) report earnings?

Hikma Pharmaceuticals PLC (GB:HIK) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).

What is Hikma Pharmaceuticals PLC (GB:HIK) earnings time?

Hikma Pharmaceuticals PLC (GB:HIK) earnings time is at Feb 19, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Hikma Pharmaceuticals PLC stock?

The P/E ratio of Hikma Pharmaceuticals is N/A.

What is GB:HIK EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing